Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (April 2024)
13 slides from Resonance Health's investor presentation, Apr 2, 2024
Slide 1: Investor Update: Acquisition of TrialsWest
Investor Update Acquisition of April 2nd 2024 Andrew Harrison, CEO 1
Slide 2: TrialsWest – Transaction snapshot
TrialsWest – Transaction snapshot TrialsWest is one of Australia’s most experienced and successful clinical research centres. It partners with the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community. ü TrialsWest is a well-respe
Slide 3: TrialsWest – Overview
TrialsWest – Overview ü Located in Perth, Western Australia ü 13 staff led by Dr Helen Pavitt, Michelle Davies, and Prof Peter Bremner who will continue with the business ü FY24 forecast revenue $2M and EBITDA of $667K ü Currently operating more than 25 trials across a range of disciplines ü World c
Slide 4: About Resonance Health
About Resonance Health Resonance Health is a globally recognised SaMD business leading the way in non-invasive MRI based quantitative organ evaluation Large Global Reach ü Gold standard in liver iron measurement ü Other key products focussing on Liver Fat and Cardiac Iron Customers ü Broad capabilit
Slide 5: Business Model
Business Model There is a strong strategic interplay between the SaMD business, our customers, and clinical trial service activities Delivers our regulatory Provides site cleared services to management SaMD Diagnostic & Pharma services to CRO’s Clinical Trial customers Services Existing Products • F
Slide 6: Clinical Trial Growth Opportunity
Clinical Trial Growth Opportunity The acquisition of TrialsWest represents a major step in the Company’s strategy to develop a site management platform to drive greater participation in the clinical trial ecosystem Other Services Imaging, Lab, Biobanks, Australian central reading Existing Products s
Slide 7: Strategic Rationale - Clinical Trial Ecosystem
Strategic Rationale - Clinical Trial Ecosystem ü Strong industry fundamentals ü Deep domain expertise and track record in providing products and services to the global clinical trials market. ü Established sophisticated systems & processes in place, including global regulatory & QA expertise ü Curre
Slide 8: Attractive Industry Thematic
Attractive Industry Thematic Australia is a highly attractive clinical trial destination – in 2019 95,000 people participated in over 1,800 trials – a 7% CAGR in the number of trials since 2015. Industry sponsored trials were worth >$1.12B. Benefits ü Approvals and regulatory system ü Public private
Slide 9: Attractive Industry Thematic
Attractive Industry Thematic Australian Clinical Trial Market Global Clinical Trial Market Key Drivers ü Increasing rapidity of technological breakthroughs ü Increase in outsourcing of trials ü Shortening development timeframes ü Increase in efficiency of non-hospital trials 9
Slide 10: Industry Fragmentation
Industry Fragmentation ü The private clinical trial sector in Australia is fragmented and relatively difficult for sponsors to deal with ü Myriad of suppliers and specialists, i.e. trial sites, imaging, lab, specialty Doctors ü Decrease in attractiveness of public hospital sites driving community gr
Slide 11: Strong Path to Growth
Strong Path to Growth Growth drivers converge to propel rapid scale-up and earnings growth New Products & Improvements Product Partners / Resellers New Geographies i.e. China, Japan Acquisitive & Organic Trial Site Expansion ASON Development ü Leveraging existing platform, products (& pipeline), glo
Slide 12: Business Outlook
Business Outlook Strong full year FY24 revenues are expected on the back of record 1H-FY24 results, ongoing execution of the Sun Pharma clinical trial, and completion of the TrialsWest acquisition ü Record 1st Half FY24 Revenue of $3.26M (+56% pcp) ü Revenue from Sun Pharma trial of $1.05M in 1st Ha
Slide 13: Disclaimer
Disclaimer This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ mater
Resonance Health — Investor Presentation (April 2024) on 6ix